Diplomat: Trump’s inauguration raises hope for end of crisis in Russia-US relationsRussian Politics & Diplomacy January 19, 16:06
Russian diplomat believes Astana meeting on Syria to strengthen ceasefire regimeRussian Politics & Diplomacy January 19, 16:00
US embassy in Russia passes to Washington invitations to Astana talks on SyriaWorld January 19, 15:39
Ankara hopes for success of Syrian talks in Astana — Turkey’s deputy PMWorld January 19, 15:35
Russia’s St. Petersburg unveils its official logo for 2020 UEFA Euro CupSport January 19, 14:47
Russia ready to help Italy in coping with earthquake aftermathWorld January 19, 14:21
Assad reveals main purpose of Astana meeting on SyriaWorld January 19, 14:20
NOVATEK’s shipyard construction is among Arctic priority projectsBusiness & Economy January 19, 14:10
Kremlin: Russia does not finance DonbassRussian Politics & Diplomacy January 19, 13:58
GENEVA, October 3. /TASS/. The Court of Arbitration for Sport (CAS) is set to announce a decision on the appeal of Russian tennis star Maria Sharapova, submitted in summer against her two-year ban, on Tuesday, October 4, the court said in its statement on Monday.
"Decision in the case of Maria Sharapova v. International Tennis Federation to be released at 3.00 pm (Swiss time) on 4 October 2016," the statement said.
On June 9, Sharapova filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed on June 8 by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
Due to the imposed ban world’s former No. 1 Sharapova had to miss the 2016 Summer Olympic Games, held in August in Brazil’s Rio de Janeiro.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.